Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.2% – What’s Next?

Zenas BioPharma, Inc. (NASDAQ:ZBIO) shares traded down 6.2% during mid-day trading on Monday . The company traded as low as $21.48 and last traded at $22.54. 132,541 shares were traded during mid-day trading, a decline of 86% from the average session volume of 933,859 shares. The stock had previously closed at $24.04.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ZBIO. Wall Street Zen raised Zenas BioPharma from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a report on Monday, December 29th. Morgan Stanley lowered shares of Zenas BioPharma from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $37.00 to $19.00 in a report on Monday, January 5th. Wedbush restated an “outperform” rating and issued a $45.00 price target on shares of Zenas BioPharma in a report on Monday, December 22nd. Finally, Jefferies Financial Group restated a “buy” rating and set a $48.00 price target on shares of Zenas BioPharma in a report on Tuesday, January 6th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $42.83.

Zenas BioPharma Stock Down 3.6%

The company has a market cap of $1.24 billion, a price-to-earnings ratio of -3.26 and a beta of -1.96. The stock’s fifty day moving average is $22.48 and its two-hundred day moving average is $27.07. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.66 and a current ratio of 5.66.

Insider Activity at Zenas BioPharma

In related news, CEO Leon O. Moulder, Jr. acquired 57,000 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was purchased at an average cost of $17.96 per share, with a total value of $1,023,720.00. Following the transaction, the chief executive officer directly owned 423,155 shares of the company’s stock, valued at $7,599,863.80. This trade represents a 15.57% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Hongbo Lu bought 25,985 shares of Zenas BioPharma stock in a transaction dated Wednesday, February 11th. The shares were acquired at an average cost of $22.50 per share, with a total value of $584,662.50. Following the completion of the purchase, the director owned 347,968 shares in the company, valued at approximately $7,829,280. This trade represents a 8.07% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 202,845 shares of company stock valued at $3,747,185 over the last 90 days. Corporate insiders own 16.50% of the company’s stock.

Institutional Trading of Zenas BioPharma

Several institutional investors and hedge funds have recently modified their holdings of the business. Quarry LP grew its stake in shares of Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after purchasing an additional 291 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in Zenas BioPharma in the 3rd quarter valued at about $30,000. GF Fund Management CO. LTD. bought a new stake in shares of Zenas BioPharma during the fourth quarter worth $38,000. BNP Paribas Financial Markets raised its holdings in Zenas BioPharma by 120.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after purchasing an additional 1,716 shares during the last quarter. Finally, CWM LLC boosted its holdings in shares of Zenas BioPharma by 48.3% in the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock worth $79,000 after buying an additional 709 shares during the last quarter.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.